Next generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematologic malignancies

Next generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematologic malignancies

The nuclear export receptor, Exportin 1 (XPO1), mediates transport of growth-regulatory proteins including tumor suppressors and is overactive in many cancers, including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and aggressive lymphomas. Oral Selective Inhibitor of Nuclear Ex...

Full description

Bibliographic Details
Main Authors: Hing, Zachary A., Fung, Ho Yee Joyce, Ranganathan, Parvathi, Mitchell, Shaneice, El-Gamal, Dalia, Woyach, Jennifer A., Williams, Katie, Goettl, Virginia M., Smith, Jordan, Yu, Xueyan, Meng, Xiaomei, Sun, Qingxiang, Cagatay, Tolga, Lehman, Amy M., Lucas, David M., Baloglu, Erkan, Shacham, Sharon, Kauffman, Michael G., Byrd, John C., Chook, Yuh Min, Garzon, Ramiro, Lapalombella, Rosa
Format: Online
Language:English
Published: 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5143172/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5143172/

Similar Items